| abstract |
【wrap up】 The present invention relates to an effector moiety that can induce intracellular effects when present in mammalian cells, the effector moiety comprising at least one saponin and a conjugated payload. The invention also relates to an antibody-drug conjugate comprising an effector moiety according to the invention or a ligand-drug conjugate comprising an effector moiety of the invention, wherein the effector moiety comprises a covalently coupled saponin. The invention also relates to a combination of therapeutic agents: (a) an effector moiety of the invention comprising at least one saponin and optionally a pharmaceutically acceptable excipient; (b) an antibody-drug conjugate or ligand. -Includes drug conjugates and optionally pharmaceutically acceptable excipients. Further, the present invention relates to a pharmaceutical composition comprising an effector portion of the present invention or an antibody-drug conjugate of the present invention or a ligand-drug conjugate of the present invention, at least one saponin covalently linked to an effector molecule. And optionally include pharmaceutically acceptable excipients. The present invention is the effector portion of the present invention or the antibody-drug conjugate of the present invention or the therapeutic agent combination of the present invention or the ligand of the present invention-drug conjugate or the pharmaceutical composition of the present invention for use as a medicine. Also related to. Finally, the invention is the effector portion of the invention or the antibody-drug conjugate of the invention or the therapeutic agent combination of the invention or the ligand of the invention for use in the treatment or prevention of cancer or autoimmune disease. -It also relates to a drug conjugate or the pharmaceutical composition of the present invention. |